Cargando…

Polyclonal Antibody Generation against PvTRAg for the Development of a Diagnostic Assay for Plasmodium vivax

The World Health Organization (WHO) has set forth a global call for eradicating malaria, caused majorly by the protozoan parasites Plasmodium falciparum and Plasmodium vivax. The lack of diagnostic biomarkers for P. vivax, especially those that differentiate the parasite from P. falciparum, signific...

Descripción completa

Detalles Bibliográficos
Autores principales: Aggarwal, Shalini, Selvaraj, Selvamano, Subramanian, Jayaprakash Nattamai, Vijayalakshmi, Mookambeswaran Arunachalam, Patankar, Swati, Srivastava, Sanjeeva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001162/
https://www.ncbi.nlm.nih.gov/pubmed/36899977
http://dx.doi.org/10.3390/diagnostics13050835
_version_ 1784904067044081664
author Aggarwal, Shalini
Selvaraj, Selvamano
Subramanian, Jayaprakash Nattamai
Vijayalakshmi, Mookambeswaran Arunachalam
Patankar, Swati
Srivastava, Sanjeeva
author_facet Aggarwal, Shalini
Selvaraj, Selvamano
Subramanian, Jayaprakash Nattamai
Vijayalakshmi, Mookambeswaran Arunachalam
Patankar, Swati
Srivastava, Sanjeeva
author_sort Aggarwal, Shalini
collection PubMed
description The World Health Organization (WHO) has set forth a global call for eradicating malaria, caused majorly by the protozoan parasites Plasmodium falciparum and Plasmodium vivax. The lack of diagnostic biomarkers for P. vivax, especially those that differentiate the parasite from P. falciparum, significantly hinders P. vivax elimination. Here, we show that P. vivax tryptophan-rich antigen (PvTRAg) can be a diagnostic biomarker for diagnosing P. vivax in malaria patients. We report that polyclonal antibodies against purified PvTRAg protein show interactions with purified PvTRAg and native PvTRAg using Western blots and indirect enzyme-linked immunosorbent assay (ELISA). We also developed an antibody-antigen-based qualitative assay using biolayer interferometry (BLI) to detect vivax infection using plasma samples from patients with different febrile diseases and healthy controls. The polyclonal anti-PvTRAg antibodies were used to capture free native PvTRAg from the patient plasma samples using BLI, providing a new expansion range to make the assay quick, accurate, sensitive, and high-throughput. The data presented in this report provides a proof of concept for PvTRAg, a new antigen, for developing a diagnostic assay for P. vivax identification and differentiation from the rest of the Plasmodium species and, at a later stage, translating the BLI assay into affordable, point-of-care formats to make it more accessible.
format Online
Article
Text
id pubmed-10001162
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100011622023-03-11 Polyclonal Antibody Generation against PvTRAg for the Development of a Diagnostic Assay for Plasmodium vivax Aggarwal, Shalini Selvaraj, Selvamano Subramanian, Jayaprakash Nattamai Vijayalakshmi, Mookambeswaran Arunachalam Patankar, Swati Srivastava, Sanjeeva Diagnostics (Basel) Article The World Health Organization (WHO) has set forth a global call for eradicating malaria, caused majorly by the protozoan parasites Plasmodium falciparum and Plasmodium vivax. The lack of diagnostic biomarkers for P. vivax, especially those that differentiate the parasite from P. falciparum, significantly hinders P. vivax elimination. Here, we show that P. vivax tryptophan-rich antigen (PvTRAg) can be a diagnostic biomarker for diagnosing P. vivax in malaria patients. We report that polyclonal antibodies against purified PvTRAg protein show interactions with purified PvTRAg and native PvTRAg using Western blots and indirect enzyme-linked immunosorbent assay (ELISA). We also developed an antibody-antigen-based qualitative assay using biolayer interferometry (BLI) to detect vivax infection using plasma samples from patients with different febrile diseases and healthy controls. The polyclonal anti-PvTRAg antibodies were used to capture free native PvTRAg from the patient plasma samples using BLI, providing a new expansion range to make the assay quick, accurate, sensitive, and high-throughput. The data presented in this report provides a proof of concept for PvTRAg, a new antigen, for developing a diagnostic assay for P. vivax identification and differentiation from the rest of the Plasmodium species and, at a later stage, translating the BLI assay into affordable, point-of-care formats to make it more accessible. MDPI 2023-02-22 /pmc/articles/PMC10001162/ /pubmed/36899977 http://dx.doi.org/10.3390/diagnostics13050835 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Aggarwal, Shalini
Selvaraj, Selvamano
Subramanian, Jayaprakash Nattamai
Vijayalakshmi, Mookambeswaran Arunachalam
Patankar, Swati
Srivastava, Sanjeeva
Polyclonal Antibody Generation against PvTRAg for the Development of a Diagnostic Assay for Plasmodium vivax
title Polyclonal Antibody Generation against PvTRAg for the Development of a Diagnostic Assay for Plasmodium vivax
title_full Polyclonal Antibody Generation against PvTRAg for the Development of a Diagnostic Assay for Plasmodium vivax
title_fullStr Polyclonal Antibody Generation against PvTRAg for the Development of a Diagnostic Assay for Plasmodium vivax
title_full_unstemmed Polyclonal Antibody Generation against PvTRAg for the Development of a Diagnostic Assay for Plasmodium vivax
title_short Polyclonal Antibody Generation against PvTRAg for the Development of a Diagnostic Assay for Plasmodium vivax
title_sort polyclonal antibody generation against pvtrag for the development of a diagnostic assay for plasmodium vivax
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001162/
https://www.ncbi.nlm.nih.gov/pubmed/36899977
http://dx.doi.org/10.3390/diagnostics13050835
work_keys_str_mv AT aggarwalshalini polyclonalantibodygenerationagainstpvtragforthedevelopmentofadiagnosticassayforplasmodiumvivax
AT selvarajselvamano polyclonalantibodygenerationagainstpvtragforthedevelopmentofadiagnosticassayforplasmodiumvivax
AT subramanianjayaprakashnattamai polyclonalantibodygenerationagainstpvtragforthedevelopmentofadiagnosticassayforplasmodiumvivax
AT vijayalakshmimookambeswaranarunachalam polyclonalantibodygenerationagainstpvtragforthedevelopmentofadiagnosticassayforplasmodiumvivax
AT patankarswati polyclonalantibodygenerationagainstpvtragforthedevelopmentofadiagnosticassayforplasmodiumvivax
AT srivastavasanjeeva polyclonalantibodygenerationagainstpvtragforthedevelopmentofadiagnosticassayforplasmodiumvivax